PMID- 23215721
OWN - NLM
STAT- MEDLINE
DCOM- 20130916
LR  - 20211203
IS  - 1873-5576 (Electronic)
IS  - 1568-0096 (Linking)
VI  - 13
IP  - 2
DP  - 2013 Feb
TI  - Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer.
PG  - 121-5
AB  - Gastric cancer remains one of the most common types of cancer worldwide, and most 
      patients present withadvanced disease. Sixty percent of these patients eventually 
      relapse after curative surgical resection, and combinationchemotherapy regimens 
      only provide limited survival benefits. Mammalian target of rapamycin (mTOR) is a 
      new targetof cancer therapies. Preclinical data suggest that the suppression of 
      the mTOR pathway inhibits the progression of gastriccancer in vitro and in animal 
      models. In clinical trials, the mTOR inhibitor, everolimus, was well tolerated in 
      phase I/IIstudies on patients with metastatic gastric cancer. The efficacy of 
      everolimus was promising in a phase II clinical trial, butin a recently published 
      phase III clinical trial everolimus monotherapy do not significantly improve the 
      overall survival ofpatients with advanced gastric cancer who had been previously 
      treated with one or two lines of systemic chemotherapy.Phosphoinositide 
      3-kinase/mTOR dual inhibitors have not yet entered early-stage clinical trials in 
      patients with advanced gastric cancer. Further studies are needed to establish 
      the role of mTOR inhibitors for the treatment of gastric cancer.
FAU - Bu, Zhaode
AU  - Bu Z
AD  - Key laboratory of Carcinogenesis and Translational Research; Ministry of 
      Education, Beijing 100142, China.
FAU - Ji, Jiafu
AU  - Ji J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Curr Cancer Drug Targets
JT  - Current cancer drug targets
JID - 101094211
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Everolimus
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Sirolimus/*analogs & derivatives/pharmacology/therapeutic use
MH  - Stomach Neoplasms/*drug therapy/pathology
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
EDAT- 2012/12/12 06:00
MHDA- 2013/09/17 06:00
CRDT- 2012/12/11 06:00
PHST- 2012/04/12 00:00 [received]
PHST- 2012/08/03 00:00 [revised]
PHST- 2012/11/29 00:00 [accepted]
PHST- 2012/12/11 06:00 [entrez]
PHST- 2012/12/12 06:00 [pubmed]
PHST- 2013/09/17 06:00 [medline]
AID - CCDT-EPUB-20121121-4 [pii]
AID - 10.2174/1568009611313020002 [doi]
PST - ppublish
SO  - Curr Cancer Drug Targets. 2013 Feb;13(2):121-5. doi: 10.2174/1568009611313020002.